Subscribe to our Newsletters !!
Eliminating sticker residue is a small yet frustra
The velocity at which pharmaceutical innovations a
The Nobel Prize in Physiology or Medicine awarded
Giesen, Germany. 26 January 2026 - At Interpack 20
Alembic Pharmaceuticals Limited (Alembic) today an
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micr
On Monday, Nacto Pharma reported that over two-fold increase in consolidated profit after the tax at Rs.181.6 crore for the second quarter ended September 30,2018. The company also posted a consolidated profit after the tax of Rs 84.4 crore in the same quarter last fiscal, Natco Pharma said in a regulatory filing.
The total revenue under the period stood at Rs. 583.5 crore. It was at Rs 432.2 crore in the year ago quarter. The company said in their board of directors meeting on Monday had agreed about the buyback of the completely paid-up equity shares of face value of Rs.2 each with a price which not exceeding Rs 1,000 per share for an aggregate amount of Rs 2,50 crores from the open market through the stock exchange mechanism.
The company said in their board of directors meeting on Monday had agreed about the buyback of the completely paid-up equity shares of face value of Rs.2 each with a price which not exceeding Rs 1,000 per share for an aggregate amount of Rs 2,50 crores from the open market through the stock exchange mechanism.
The maximum buyback size represents 8.10 per cent and 8.22 per cent of the aggregate of the total paid up equity capital and free reserves, respectively, of the company, it added.
